"Emerging Fusion Protein Technologies Drive Innovation in Targeted Therapies Across Autoimmune, Cancer, Metabolic, and Cardiovascular Diseases" Boston, Dec. 11, 2025 (GLOBE NEWSWIRE) -- According to ...
Dynamic remodeling of the endomembrane system is a core biological process essential for maintaining cellular compartmentalization and homeostasis. Proteins enriched in intrinsically disordered ...
Global contract development and manufacturing organization (CDMO) WuXi Biologics announced a partnership with Taiwan-based ...
BUFFALO, N.Y., — Many childhood cancers start with a hijacking at the molecular level. A group of abnormal proteins known as fusion proteins aberrantly engage with a collection of proteins that ...
Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University have ...
Taiwanese biotech HanchorBio (TPEx: 7827) has signed a strategic collaboration with WuXi Biologics (HKEX: 2269) to develop ...
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for ...
The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...
Biotium’s ViaTag™ Haloalkane Ligands deliver bright, durable labeling that remains robust through fixation, permeabilization, ...
News-Medical.Net on MSN
WuXi Biologics and Hanchorbio enter strategic partnership to advance next-generation bi- and multi-functional fusion protein pipeline
WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc., a global clinical-stage biotechnology company advancing next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results